Microcrystalline cellulose induces time-dependent lung functional and inflammatory changes.

We determined whether microcrystalline cellulose (MCC), a component of pharmaceutical tablets, induces pulmonary changes. In vivo [resistive and viscoelastic pressures (DeltaP(1) and DeltaP(2)), static elastance (E(L))] and in vitro [tissue resistance (R), elastance (E), and hysteresivity (eta)] lung mechanics, histology, and bronchoalveolar lavage fluid (BALF) were analyzed 3h, 24h, and 3, 15 and 30 days after intratracheal instillation of saline (C) or MCC in BALB/c mice. DeltaP(1) increased at 3h, remaining higher than C until day 3, while E(L) and DeltaP(2) increased only at 24h. At 3 days all mechanical parameters returned to baseline. R and E increased only at 24h. MCC increased alveolar collapse and the number of neutrophils in BALF at 3h, until 3 and 15 days, respectively. At 3 days MCC migrate from the airways into the parenchyma, where they were observed until 30 days. In conclusion, microcrystalline cellulose yielded an acute and self-limited inflammation that impaired lung mechanics.

Effects of propofol on respiratory mechanic and lung histology in normal rats.

BACKGROUND: Propofol is able to reduce airway resistance in lungs with previous airway constriction. The aim of this study was to evaluate the effects of propofol on respiratory mechanics in normal rats and to correlate these parameters with lung histology, to define the sites of action of propofol. METHODS: Sixteen Wistar rats were divided into two groups of eight animals. Rats were sedated (diazepam) and anaesthetized with pentobarbital sodium (C) or propofol (P), and paralysed. Respiratory system, lung, and chest wall resistive, elastic, and viscoelastic/inhomogeneous pressures were computed using the end-inflation occlusion method. RESULTS: Lung resistive pressure was smaller in group P (0.29 kPa (0.05)) than group C (0.37 kPa (0.04)) (P=0.007). The internal diameter of the central airways was greater in group P than C (P=0.01). CONCLUSION: Propofol acts at the airway level decreasing respiratory system and lung impedances as a result of central airway dilation.

Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury.

The effects of LASSBio596, a phosphodiesterase type-4 and -5 inhibitor, were tested in Escherichia coli lipopolysaccharide (LPS)-induced acute lung injury. Twenty-four BALB/c mice were randomly divided into four groups. In the control group, saline (0.05 mL) was injected intratracheally (i.t.). The LPS group received LPS (10 microg i.t., 0.05 mL). In the LASSBio596 groups, LASSBio596 (10 mg x kg(-1), 0.2 mL) was injected intraperitoneally 1 h before or 6 h after LPS administration. After 24 h, in vivo (lung resistive and viscoelastic pressures, and static and dynamic elastances) and in vitro (tissue resistance, elastance and hysteresivity) pulmonary mechanics, lung morphometry and collagenous fibre content were computed. Neutrophils and tumour necrosis factor (TNF)-alpha levels were evaluated in the bronchoalveolar lavage fluid. LASSBio596 prevented the changes in lung mechanics, and inhibited neutrophilic recruitment, TNF-alpha release, bronchoconstriction, alveolar collapse and the increment of collagen fibre content induced by LPS, independently of the moment of injection. In conclusion, LASSBio596 modulated the lung inflammatory process and had the potential to block fibroproliferation. Thus, agents that inhibit phosphodiesterase 4 and 5 simultaneously may be a useful adjunct therapy for acute lung injury.